PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9168437-1 1997 We demonstrate that N-(4-hydroxyphenyl)-all-trans-retinamide (4-HPR), a synthetic retinoic acid (RA) derivative, is a potent and selective inducer of apoptosis in malignant T lymphoid cells, but has little effect on normal lymphoid cells of the thymus or spleen. Fenretinide 20-60 haptoglobin-related protein Homo sapiens 64-67 9125196-7 1997 We found that 4-hydroxyphenylretinamide (4-HPR) inhibited the catabolism of RA. Fenretinide 14-39 haptoglobin-related protein Homo sapiens 43-46 8621233-0 1996 Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Fenretinide 26-37 haptoglobin-related protein Homo sapiens 40-43 8993839-1 1997 N-(4-Hydroxyphenyl)retinamide (4-HPR, Fenretinide) is a retinoid derivative with antineoplastic activity in various tumor types including prostate carcinoma. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 8993839-1 1997 N-(4-Hydroxyphenyl)retinamide (4-HPR, Fenretinide) is a retinoid derivative with antineoplastic activity in various tumor types including prostate carcinoma. Fenretinide 38-49 haptoglobin-related protein Homo sapiens 33-36 9018085-0 1996 Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. Fenretinide 34-45 haptoglobin-related protein Homo sapiens 49-52 9018085-1 1996 Eighteen patients with facial actinic keratoses were treated with the retinoid fenretinide (4-HPR), applied topically twice-daily for 3 months. Fenretinide 79-90 haptoglobin-related protein Homo sapiens 94-97 9063520-0 1996 Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability. Fenretinide 38-49 haptoglobin-related protein Homo sapiens 53-56 9063520-1 1996 BACKGROUND: Fenretinide (4-HPR) is a synthetic retinoid being clinically tested in the chemoprevention of different tumors and precancerous lesions. Fenretinide 12-23 haptoglobin-related protein Homo sapiens 27-30 8687125-1 1996 The O-glucuronide analog of N-(4-hydroxyphenyl)retinamide (4-HPROG) has shown a greater chemopreventive activity than the parent N-(4-hydroxyphenyl)retinamide (4-HPR). Fenretinide 28-57 haptoglobin-related protein Homo sapiens 61-64 8640761-1 1996 The activities of N-(4-hydroxyphenyl)retinamide [(4-HPR), Fenretinide] and all-trans-retinoic acid (RA) were determined for (a) the inhibition of cell proliferation; (b) the activation of human retinoid receptor-mediated target gene expression; (c) the inhibition of estradiol- and progesterone-induced gene activation in breast cancer cell lines; and (d) the regulation of the expression of tumor suppressor retinoblastoma protein. Fenretinide 18-47 haptoglobin-related protein Homo sapiens 52-55 8948605-1 1996 Both retinoic acid (RA) and the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) have shown efficacy in head and neck cancer chemoprevention trials. Fenretinide 51-80 haptoglobin-related protein Homo sapiens 83-86 8713132-0 1996 Differential effects of retinoic acid (RA) and N-(4-hydroxyphenyl) retinamide (4-HPR) on cell growth, induction of differentiation, and changes in p34cdc2, Bcl-2, and actin expression in the human promyelocytic HL-60 leukemic cells. Fenretinide 47-77 haptoglobin-related protein Homo sapiens 81-84 8651965-1 1996 OBJECTIVE: To evaluate the efficacy and tolerability of N-[4 hydroxyphenyl] retinamide (4-HPR), a synthetic retinoid, in the treatment of rheumatoid arthritis (RA). Fenretinide 56-86 haptoglobin-related protein Homo sapiens 90-93 8595390-0 1995 The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) exerts antiproliferative and apoptosis-inducing effects in the androgen-independent human prostatic JCA-1 cells. Fenretinide 23-53 haptoglobin-related protein Homo sapiens 57-60 7473815-3 1995 Fenretinide [N-(4-hydroxyphenyl)retinamide; HPR] is a synthetic retinoid with minimal toxicity and favorable pharmacokinetics during long-term administration to patients in clinical trials. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 44-47 7473815-3 1995 Fenretinide [N-(4-hydroxyphenyl)retinamide; HPR] is a synthetic retinoid with minimal toxicity and favorable pharmacokinetics during long-term administration to patients in clinical trials. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 44-47 7586155-0 1995 N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 7586155-2 1995 N-(4-hydroxyphenyl) retinamide (4-HPR), a derivative of all-trans-retinoic acid (RA) is currently in clinical trials as a chemopreventive agent for breast cancer. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 34-37 21552857-2 1995 All-trans retinoic acid (ATRA) and N-(4-hydroxyphenyl)retinamide (4HPR) are currently being evaluated in clinical trials for their potential use in cancer chemoprevention and therapy. Fenretinide 35-64 haptoglobin-related protein Homo sapiens 67-70 9816026-1 1995 The synthetic retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR; Fenretinide), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown. Fenretinide 24-53 haptoglobin-related protein Homo sapiens 57-60 9816026-1 1995 The synthetic retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR; Fenretinide), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown. Fenretinide 62-73 haptoglobin-related protein Homo sapiens 57-60 21607448-1 1994 Fenretinide (4-HPR), a synthetic amide derivative of retinoic acid, has proven effective in preventing chemically induced mammary carcinoma in rodents. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 8033144-1 1994 The efficacy of the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been demonstrated in the inhibition of cancers in a variety of tissues. Fenretinide 29-58 haptoglobin-related protein Homo sapiens 62-65 8382073-3 1993 Attention is presently focused on two compounds, the synthetic retinoid fenretinide (4-HPR) and the antioestrogen tamoxifen, and their possible synergism. Fenretinide 72-83 haptoglobin-related protein Homo sapiens 87-90 8149338-0 1994 Successful topical treatment of oral lichen planus and leukoplakias with fenretinide (4-HPR). Fenretinide 73-84 haptoglobin-related protein Homo sapiens 88-91 8221674-1 1993 Fenretinide or N-(4-hydroxyphenyl) retinamide (4HPR) is a synthetic retinoid currently being tested clinically, which can inhibit the development and the growth of breast and prostate cancers in rodents. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 48-51 8221674-1 1993 Fenretinide or N-(4-hydroxyphenyl) retinamide (4HPR) is a synthetic retinoid currently being tested clinically, which can inhibit the development and the growth of breast and prostate cancers in rodents. Fenretinide 15-45 haptoglobin-related protein Homo sapiens 48-51 8217599-1 1993 N-(4-hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoid which reduces the incidence of experimental tumours in animals and has been chosen for its weak toxicity to be tested as a chemopreventive agent in humans. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 34-37 8319203-1 1993 Fenretinide (HPR), 13-cis-retinoic acid, and all-trans-retinoic acid are vitamin A derivatives used in the treatment of cancer and severe acne. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 13-16 8297658-0 1993 Mammographic patterns in breast cancer chemoprevention with fenretinide (4-HPR). Fenretinide 60-71 haptoglobin-related protein Homo sapiens 75-78 8007703-1 1993 Fenretinide (4-HPR), a synthetic derivative of retinoic acid, has proven effective at inhibiting in vitro breast cancer cell growth and preventing the progression of chemically induced mammary carcinoma in rodents. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 8412202-0 1993 Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 8412202-2 1993 The goal of the trial is to evaluate the effectiveness of fenretinide (4-HPR) in preventing relapses, new localizations, and carcinomas in patients with benign postoperative diagnoses who have been surgically treated for oral leukoplakias. Fenretinide 58-69 haptoglobin-related protein Homo sapiens 73-76 8208624-1 1994 The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) has been demonstrated to inhibit the development of primary and metastatic neoplasms in several animal models. Fenretinide 23-53 haptoglobin-related protein Homo sapiens 57-60 7685988-1 1993 The in vitro anticlastogenic effects of a new synthetic retinoid derivative, N-(4-hydroxyphenyl)-retinamide (4-HPR), were studied in two human lymphoblastid cell lines (3640P and 4087P). Fenretinide 77-107 haptoglobin-related protein Homo sapiens 111-114 1305675-4 1992 In vitro assays indicate that fenretinide (4-HPR), alpha-interferon, and 5-fluorouracil possess significant antitumoral activity in human transitional cell carcinoma (TCC) lines. Fenretinide 30-41 haptoglobin-related protein Homo sapiens 45-48 1306735-0 1992 Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Fenretinide 100-111 haptoglobin-related protein Homo sapiens 115-118 1305678-1 1992 The ability of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) to affect the outcome of previously resected superficial bladder cancer was investigated in a pilot study using DNA content flow cytometry and conventional cytology as intermediate endpoints. Fenretinide 38-67 haptoglobin-related protein Homo sapiens 71-74 1535505-1 1992 Fenretinide [N-(4-hydroxyphenyl)retinamide, 4-HPR] is an effective agent for the inhibition of N-nitroso-N-methylurea-induced breast cancer in rats. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 46-49 2527636-0 1989 Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Fenretinide 49-78 haptoglobin-related protein Homo sapiens 82-85 1835622-0 1991 Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Fenretinide 26-37 haptoglobin-related protein Homo sapiens 41-44 2694156-3 1989 N-(4-hydroxyphenyl)retinamide (4-HPR) currently appears to be the most efficacious retinoid against carcinogen-induced breast, urinary bladder, and lung cancer in rodents. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 2527636-1 1989 A study was conducted to determine whether N-(4-hydroxyphenyl)retinamide (4-HPR) affects the development of new mammary tumors subsequent to the surgical removal of the first palpable tumor. Fenretinide 43-72 haptoglobin-related protein Homo sapiens 76-79 2643696-3 1989 N-(4-hydroxyphenyl) retinamide (4-HPR) currently appears to be the most efficaceous retinoid against carcinogen-induced breast, urinary bladder, and lung cancer in rodents. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 34-37 33423090-0 2021 A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Fenretinide 31-42 haptoglobin-related protein Homo sapiens 46-49 32266855-1 2020 Fenretinide (4-HPR), as a semi-synthetic retinoid, has apoptosis-promoting effects as a single agent and chemotherapy synergist in vitro. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 32366203-1 2020 Fenretinide (4-HPR), a synthetic retinoid, has shown its antitumor activity in many tumor types with low cytotoxicity to normal cells and high clinical safety. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 32266855-3 2020 In this research, a new TPGS-Soluplus mixed micelles were developed which encapsulation efficiencies of paclitaxel (PTX) and fenretinide (4-HPR) were as high as 98%, and the average diameter of the micelles was 66.26 nm. Fenretinide 126-137 haptoglobin-related protein Homo sapiens 141-144 32497314-1 2020 Fenretinide (4-HPR) is a synthetic derivative of All-Trans-Retinoic Acid (ATRA) characterised by improved therapeutic properties and toxicological profile relative to ATRA. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 28340497-1 2017 We previously reported that concurrent ketoconazole, an oral anti-fungal agent and P450 enzyme inhibitor, increased plasma levels of the cytotoxic retinoid, fenretinide (4-HPR) in mice. Fenretinide 157-168 haptoglobin-related protein Homo sapiens 172-175 31484706-2 2019 Fenretinide (4-HPR) is a cytotoxic retinoid with clinical activity in recurrent neuroblastoma and venetoclax (ABT-199) is a selective inhibitor of the antiapoptotic protein B-cell lymphoma-2 (BCL-2). Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 30061204-1 2018 BACKGROUND/AIM: N-(4-hydroxyphenyl)retinamide (4-HPR) is a synthetic retinoid, less toxic than the parent all-trans retinoic acid (RA). Fenretinide 16-45 haptoglobin-related protein Homo sapiens 49-52 28988109-3 2017 We show here for the first time that ZIKV NS5 is recognized with high nanomolar affinity by the host cell importin alpha/beta1 heterodimer, and that this interaction can be blocked by the novel DENV NS5 targeting inhibitor N-(4-hydroxyphenyl) retinamide (4-HPR). Fenretinide 223-253 haptoglobin-related protein Homo sapiens 257-260 30836314-9 2019 The validated method was successfully applied to the analyses of pharmacokinetic samples from patients treated with safingol and all-trans-N-(4-hydroxyphenyl)retinamide; (fenretinide, 4-HPR) in a current phase I clinical trial (SPOC-2010-002, ClinicalTrials.gov Identifier: NCT01553071). Fenretinide 129-168 haptoglobin-related protein Homo sapiens 186-189 30251395-2 2018 The synthetic retinoid fenretinide (4-HPR) achieved multiple complete responses in relapse/refractory neuroblastoma in early-phase clinical trials, has low systemic toxicity, and has been considered for maintenance therapy clinical trials. Fenretinide 23-34 haptoglobin-related protein Homo sapiens 38-41 29767236-1 2018 N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide), which is a synthetic analog of all-trans retinoic acid (ATRA), effectively inhibits the growth of several types of tumor cells; however, its molecular mechanism remains unclear. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 29767236-1 2018 N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide), which is a synthetic analog of all-trans retinoic acid (ATRA), effectively inhibits the growth of several types of tumor cells; however, its molecular mechanism remains unclear. Fenretinide 40-51 haptoglobin-related protein Homo sapiens 33-36 28429653-1 2017 Fenretinide (4-HPR) is a synthetic retinoid that has cytotoxic activity against cancer cells. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 26220867-1 2015 Fenretinide, N-(4-hydroxyphenyl)retinamide, (4-HPR), a synthetic retinoid, owes its cancer-toxic effects in part to the generation of ceramide, a potent tumor-suppressing sphingolipid. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 47-50 28275870-1 2017 PURPOSE: By a scaffold shortening strategy, a small series of retinoidal amides fenretinide (4-HPR) analogs have been synthesized from alpha, beta-ionones and tested for their antiproliferative and differentiating activities, and antioxidant effect. Fenretinide 80-91 haptoglobin-related protein Homo sapiens 95-98 27085050-3 2016 In this study we tested the hypothesis that combining Foscan-mediated PDT with desaturase inhibitor fenretinide (HPR) enhances cancer cell killing. Fenretinide 100-111 haptoglobin-related protein Homo sapiens 113-116 28448568-0 2017 Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets beta-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Delta4-desaturase 1. Fenretinide 22-33 haptoglobin-related protein Homo sapiens 130-133 28448568-1 2017 The therapeutic capacity of fenretinide (N-[4-hydroxyphenyl] retinamide; 4-HPR) has been demonstrated for several conditions, including cancer, obesity, diabetes, and ocular disease. Fenretinide 28-39 haptoglobin-related protein Homo sapiens 75-78 28448568-1 2017 The therapeutic capacity of fenretinide (N-[4-hydroxyphenyl] retinamide; 4-HPR) has been demonstrated for several conditions, including cancer, obesity, diabetes, and ocular disease. Fenretinide 41-71 haptoglobin-related protein Homo sapiens 75-78 28448568-3 2017 We hypothesized that investigation of two of the major physiological metabolites of fenretinide, N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR), might begin to resolve the multifaceted effects of this synthetic retinoid. Fenretinide 84-95 haptoglobin-related protein Homo sapiens 181-184 28448568-6 2017 The data demonstrate that while fenretinide is an inhibitor of the activities of these three enzymes, that 3-keto-HPR is a more potent inhibitor of all three enzymes, potentially mediating most of the in vivo beneficial effects of fenretinide. Fenretinide 231-242 haptoglobin-related protein Homo sapiens 114-117 28179290-1 2017 BACKGROUND/AIM: Combining an anticancer agent fenretinide (HPR) or C6-pyridinium ceramide (LCL29) with Foscan-mediated photodynamic therapy (FoscanPDT) is expected to augment anticancer benefits of each substance. Fenretinide 46-57 haptoglobin-related protein Homo sapiens 59-62 27701038-1 2017 A simple and accurate high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the determination of N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) and its metabolites, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) and N-(4-methoxyphenyl)retinamide (4-MPR), in human plasma. Fenretinide 143-172 haptoglobin-related protein Homo sapiens 189-192 27701038-1 2017 A simple and accurate high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the determination of N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) and its metabolites, 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) and N-(4-methoxyphenyl)retinamide (4-MPR), in human plasma. Fenretinide 143-172 haptoglobin-related protein Homo sapiens 260-263 27530131-2 2016 Fenretinide (4-HPR) is a synthetic retinoid. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 27367907-0 2016 Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/beta-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 27367907-3 2016 N-(4-Hydroxyphenyl) retinamide (4-HPR, fenretinide), a synthetic analogue of all-trans retinoic acid, has emerged as a promising and well-tolerated cancer chemopreventive and chemotherapeutic agent for various neoplasms, from breast cancer to neuroblastoma. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 34-37 27367907-3 2016 N-(4-Hydroxyphenyl) retinamide (4-HPR, fenretinide), a synthetic analogue of all-trans retinoic acid, has emerged as a promising and well-tolerated cancer chemopreventive and chemotherapeutic agent for various neoplasms, from breast cancer to neuroblastoma. Fenretinide 39-50 haptoglobin-related protein Homo sapiens 34-37 26220867-1 2015 Fenretinide, N-(4-hydroxyphenyl)retinamide, (4-HPR), a synthetic retinoid, owes its cancer-toxic effects in part to the generation of ceramide, a potent tumor-suppressing sphingolipid. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 47-50 25313218-4 2015 We screened a library of bioactive lipids and modulators of lipid metabolism and identified 4-hydroxyphenyl retinamide (4-HPR) (fenretinide) as an inhibitor of DENV in cell culture. Fenretinide 92-118 haptoglobin-related protein Homo sapiens 122-125 25576804-4 2015 In the current study, N-(4-hydroxyphenyl)retinamide (4-HPR), a synthetic retinoid, was used as a drug model of ROS induction to investigate its synergistic effect with AgNPs. Fenretinide 22-51 haptoglobin-related protein Homo sapiens 55-58 25313218-4 2015 We screened a library of bioactive lipids and modulators of lipid metabolism and identified 4-hydroxyphenyl retinamide (4-HPR) (fenretinide) as an inhibitor of DENV in cell culture. Fenretinide 128-139 haptoglobin-related protein Homo sapiens 122-125 24392637-4 2014 RESULTS: Increasing concentrations of N-(4-hydroxyphenyl) retinamide (4-HPR)-treatment pushed autophagy down to apoptosis in a dose-dependent manner, and 4-HPR-induced ROS contribute to this process. Fenretinide 38-68 haptoglobin-related protein Homo sapiens 72-75 24392637-4 2014 RESULTS: Increasing concentrations of N-(4-hydroxyphenyl) retinamide (4-HPR)-treatment pushed autophagy down to apoptosis in a dose-dependent manner, and 4-HPR-induced ROS contribute to this process. Fenretinide 38-68 haptoglobin-related protein Homo sapiens 156-159 24253178-2 2014 The retinoic acid analogue, fenretinide (4-hydroxyphenyl retinamide; 4-HPR), induces apoptosis in neuroblastoma cells in vitro and is currently in clinical trials for children with refractory neuroblastoma. Fenretinide 28-39 haptoglobin-related protein Homo sapiens 71-74 24755119-2 2014 The combination of fenretinide (4-HPR), a synthetic retinoid inducing apoptosis by ROS generation, and TRAIL, a cell death ligand inducing caspase-dependent apoptosis, might result in more powerful cytotoxic activity. Fenretinide 19-30 haptoglobin-related protein Homo sapiens 34-37 24253178-2 2014 The retinoic acid analogue, fenretinide (4-hydroxyphenyl retinamide; 4-HPR), induces apoptosis in neuroblastoma cells in vitro and is currently in clinical trials for children with refractory neuroblastoma. Fenretinide 41-67 haptoglobin-related protein Homo sapiens 71-74 24040340-1 2013 We previously reported that fenretinide (4-HPR) was cytotoxic to acute lymphoblastic leukemia (ALL) cell lines in vitro in association with increased levels of de novo synthesized dihydroceramides, the immediate precursors of ceramides. Fenretinide 28-39 haptoglobin-related protein Homo sapiens 43-46 23813912-1 2013 BACKGROUND: A phase I study was conducted to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics of fenretinide (4-HPR) delivered in an oral powderized lipid complex (LXS) in patients with relapsed/refractory neuroblastoma. Fenretinide 140-151 haptoglobin-related protein Homo sapiens 155-158 23792118-5 2013 Among them, fenretinide (HPR) has been considered one of the most promising anti-tumor agent but it is partially efficacious due to both poor aqueous solubility and rapid metabolism. Fenretinide 12-23 haptoglobin-related protein Homo sapiens 25-28 22427354-6 2012 LC-MS/MS analyses of post-treatment samples revealed a delivery gradient with highest fenretinide levels achieved at the patch-mucosal interface (no metabolites), pharmacologically active levels in fenretinide-treated oral mucosa (mean: 5.65 muM; trace amounts of 4-oxo-4-HPR) and undetectable sera levels. Fenretinide 198-209 haptoglobin-related protein Homo sapiens 272-275 23052481-3 2013 Fenretinide (4-HPR) is a synthetic retinoid that has shown clinical activity in recurrent NB and is cytotoxic to a variety of cancer cells, in part via the accumulation of dihydroceramides, which are precursors of GD2. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 23052481-5 2013 Here, we demonstrate for the first time that pretreatment of fenretinide-resistant NB cells with 4-HPR significantly enhanced ch14.18/CHO-mediated CDC and ADCC and AICC by both human natural killer cells and peripheral blood mononuclear cells. Fenretinide 61-72 haptoglobin-related protein Homo sapiens 99-102 22488409-1 2012 Synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been reported to exhibit anti-invasive and anti-metastatic activities by suppressing the enzymatic activity of matrix metalloproteinase (MMP)-9, but the underlying mechanism remains unclear. Fenretinide 19-48 haptoglobin-related protein Homo sapiens 52-55 22532987-1 2012 Fenretinide (4-HPR) cytotoxicity relative to glutathione levels in pediatric acute lymphoblastic leukemia cell lines cultured at bone marrow level hypoxia (5% O2) is evaluated. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 22498172-2 2012 We explored efficacy of N-(4-hydroxyphenyl) retinamide (4-HPR) and (-)-epigallocatechin-3-gallate (EGCG) in altering expression of oncogenic microRNAs (OGmiRs) and tumor suppressor miRs (TSmiRs) for controlling growth of human malignant neuroblastoma SK-N-BE2 and IMR-32 cells. Fenretinide 24-54 haptoglobin-related protein Homo sapiens 58-61 22427354-9 2012 Human oral mucosal correlative studies showed substantial interdonor variations in levels of the enzyme (cytochrome P450 3A4-CYP3A4) responsible for conversion of fenretinide to its highly active metabolite, 4-oxo-4-HPR. Fenretinide 163-174 haptoglobin-related protein Homo sapiens 216-219 22221098-2 2012 METHODS: We synthesised an amphiphilic dextrin derivative (DX-OL) able to host fenretinide (4-HPR) by complexation. Fenretinide 79-90 haptoglobin-related protein Homo sapiens 94-97 22428532-1 2012 4-(Hydroxyphenyl)retinamide (4-HPR) is a synthetic retinoid with a strong apoptotic effect towards different cancer cell lines in vitro, and it is currently tested in clinical trials. Fenretinide 0-27 haptoglobin-related protein Homo sapiens 31-34 22061047-1 2011 BACKGROUND: N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, but little is known regarding mechanisms leading to chemoresistance. Fenretinide 12-41 haptoglobin-related protein Homo sapiens 45-48 22500077-0 2012 Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk? Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 22500077-4 2012 Fenretinide (4-HPR) is the most studied retinoid in breast cancer chemoprevention clinical trials due to its selective accumulation in breast tissue and its favorable toxicological profile. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 21964808-2 2012 A retinoid analogue, fenretinide [N-(4-hydroxyphenyl) retinamide; 4-HPR] can induce apoptosis in neuroblastoma cell lines and could have clinical use after therapy with 13cisRA. Fenretinide 21-32 haptoglobin-related protein Homo sapiens 80-83 21964808-2 2012 A retinoid analogue, fenretinide [N-(4-hydroxyphenyl) retinamide; 4-HPR] can induce apoptosis in neuroblastoma cell lines and could have clinical use after therapy with 13cisRA. Fenretinide 34-64 haptoglobin-related protein Homo sapiens 80-83 21933888-1 2011 PURPOSE: Fenretinide (4-HPR) is a cytotoxic retinoid with minimal systemic toxicity that has shown clinical activity against recurrent high-risk neuroblastoma. Fenretinide 9-20 haptoglobin-related protein Homo sapiens 24-27 22183330-0 2012 The mechanism of fenretinide (4-HPR) inhibition of beta-carotene monooxygenase 1. Fenretinide 17-28 haptoglobin-related protein Homo sapiens 32-35 22761939-1 2012 BACKGROUND: Fenretinide (4-HPR) is a synthetic retinoid that exhibits potent antitumor and chemopreventive activities against different malignancies, including ovarian tumors. Fenretinide 12-23 haptoglobin-related protein Homo sapiens 27-30 21908574-0 2011 Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children"s Oncology Group. Fenretinide 32-57 haptoglobin-related protein Homo sapiens 61-64 22061047-1 2011 BACKGROUND: N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a synthetic retinoid with potent pro-apoptotic activity against several types of cancer, but little is known regarding mechanisms leading to chemoresistance. Fenretinide 50-61 haptoglobin-related protein Homo sapiens 45-48 21723035-5 2011 Over-expression of TMEM14A in U87MG cells inhibited N-(4-hydroxyphenyl)retinamide (4-HPR)-induced apoptosis. Fenretinide 52-81 haptoglobin-related protein Homo sapiens 85-88 21951911-2 2011 N-(4-hydroxy phenyl) retinamide (4-HPR or fenretinide) is a potential chemotherapeutic for RTs with activity correlated to its ability to down-modulate Cyclin D1. Fenretinide 0-31 haptoglobin-related protein Homo sapiens 35-38 21951911-2 2011 N-(4-hydroxy phenyl) retinamide (4-HPR or fenretinide) is a potential chemotherapeutic for RTs with activity correlated to its ability to down-modulate Cyclin D1. Fenretinide 42-53 haptoglobin-related protein Homo sapiens 35-38 21822457-3 2011 We examined for the first time the efficacy of N-(4-hydroxyphenyl) retinamide (4-HPR) and genistein (GST) alone and also in combination for controlling growth of human Ewing"s sarcoma SK-N-MC and RD-ES xenografts. Fenretinide 47-77 haptoglobin-related protein Homo sapiens 81-84 21543327-2 2011 We previously demonstrated that fenretinide (4-HPR) inhibited DES activity in SMS-KCNR neuroblastoma cells. Fenretinide 32-43 haptoglobin-related protein Homo sapiens 47-50 22468231-4 2011 We evaluated synergistic efficacy of N-(4-hydroxyphenyl) retinamide (4-HPR) and genistein (GST) for induction of apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells in culture and activation of multiple pathways for increasing apoptosis in ectopic and orthotopic neuroblastoma xenografts in nude mice. Fenretinide 37-67 haptoglobin-related protein Homo sapiens 71-74 21072519-1 2011 PURPOSE: Although fenretinide (4-HPR) has been studied in breast cancer and in neuroblastoma, little is known regarding its activity in pancreatic cancer, a neoplasm for which there are few therapeutic options. Fenretinide 18-29 haptoglobin-related protein Homo sapiens 33-36 21557271-1 2011 BACKGROUND: The purpose of this study was to determine whether the therapeutic efficacy of fenretinide (4-HPR), a ceramide-generating anticancer agent, could be enhanced in prostate cancer cells by inclusion of a novel synthetic acid ceramidase (AC) inhibitor, DM102, a pivaloylamide of a 2-substituted aminoethanol. Fenretinide 91-102 haptoglobin-related protein Homo sapiens 106-109 21498721-1 2011 BACKGROUND: The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability has hindered clinical assessment. Fenretinide 35-46 haptoglobin-related protein Homo sapiens 81-84 21498721-1 2011 BACKGROUND: The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide, 4-HPR) has shown promising anticancer activity in preclinical studies, but its limited oral bioavailability has hindered clinical assessment. Fenretinide 48-77 haptoglobin-related protein Homo sapiens 81-84 21054342-1 2011 BACKGROUND AND PURPOSE: Fenretinide (4-HPR) is a retinoic acid analogue, currently used in clinical trials in oncology. Fenretinide 24-35 haptoglobin-related protein Homo sapiens 39-42 21117610-1 2010 Intravenous fenretinide (4-HPR), a cytotoxic retinoid, is being evaluated as part of a phase I clinical trial for patients with hematologic malignancies. Fenretinide 12-23 haptoglobin-related protein Homo sapiens 27-30 20679253-2 2010 Treatment of cancer cells with N-(4-hydroxyphenyl) retinamide (4-HPR) induces apoptosis through destabilization of mitochondrial membrane and activation of caspase-mediated apoptotic pathways. Fenretinide 31-61 haptoglobin-related protein Homo sapiens 65-68 20637870-0 2010 HIF-1alpha-dependent autophagy protects HeLa cells from fenretinide (4-HPR)-induced apoptosis in hypoxia. Fenretinide 56-67 haptoglobin-related protein Homo sapiens 71-74 20637870-2 2010 N-(4-Hydroxyphenyl)retinamide (4-HPR) exhibits potent anticancer and chemopreventive activities, but its inefficiency under hypoxia, through undetermined mechanisms, may contribute to its lack of activity in clinical trials. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 20976277-1 2010 BACKGROUND: The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a polar metabolite of fenretinide (4-HPR) very effective in killing cancer cells of different histotypes, able to inhibit 4-HPR-resistant cell growth and to act synergistically in combination with the parent drug. Fenretinide 100-111 haptoglobin-related protein Homo sapiens 70-73 20976277-1 2010 BACKGROUND: The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a polar metabolite of fenretinide (4-HPR) very effective in killing cancer cells of different histotypes, able to inhibit 4-HPR-resistant cell growth and to act synergistically in combination with the parent drug. Fenretinide 100-111 haptoglobin-related protein Homo sapiens 115-118 20976277-1 2010 BACKGROUND: The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a polar metabolite of fenretinide (4-HPR) very effective in killing cancer cells of different histotypes, able to inhibit 4-HPR-resistant cell growth and to act synergistically in combination with the parent drug. Fenretinide 100-111 haptoglobin-related protein Homo sapiens 115-118 20532509-1 2010 PURPOSE: Fenretinide (4-HPR), a synthetic retinoid currently used in clinic for cancer therapy and prevention, markedly lowers plasma retinol levels, an effect associated with nyctalopia. Fenretinide 9-20 haptoglobin-related protein Homo sapiens 24-27 20628055-1 2010 Increased generation of dihydrosphingosine (DHS), a bioactive sphingolipid, has been implicated in the cytotoxicity of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) in tumor cells. Fenretinide 142-171 haptoglobin-related protein Homo sapiens 175-178 20687958-7 2010 Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC via induction of the Brg-1 in a dose-dependent manner. Fenretinide 15-26 haptoglobin-related protein Homo sapiens 61-64 20687958-7 2010 Interestingly, fenretinide [N-4(hydroxyphenyl) retinamide, 4-HPR], a synthetic retinoid with anti-cancer properties, was found to up-regulate the transcription, expression and secretion of SPARC via induction of the Brg-1 in a dose-dependent manner. Fenretinide 28-57 haptoglobin-related protein Homo sapiens 61-64 19996280-1 2009 The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), a metabolite of fenretinide (4-HPR) present in plasma of 4-HPR-treated patients, is very effective in inducing growth inhibition and apoptosis in several cancer cell lines. Fenretinide 80-91 haptoglobin-related protein Homo sapiens 58-61 20034809-1 2010 Clinical trials have revealed that N-(4-hydroxyphenyl) retinamide (4HPR; fenretinide), a synthetic retinoic acid derivative, is a highly active and promising therapeutic and chemopreventive agent. Fenretinide 35-65 haptoglobin-related protein Homo sapiens 68-71 20034809-1 2010 Clinical trials have revealed that N-(4-hydroxyphenyl) retinamide (4HPR; fenretinide), a synthetic retinoic acid derivative, is a highly active and promising therapeutic and chemopreventive agent. Fenretinide 73-84 haptoglobin-related protein Homo sapiens 68-71 19996280-1 2009 The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), a metabolite of fenretinide (4-HPR) present in plasma of 4-HPR-treated patients, is very effective in inducing growth inhibition and apoptosis in several cancer cell lines. Fenretinide 80-91 haptoglobin-related protein Homo sapiens 95-98 19996280-1 2009 The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR), a metabolite of fenretinide (4-HPR) present in plasma of 4-HPR-treated patients, is very effective in inducing growth inhibition and apoptosis in several cancer cell lines. Fenretinide 80-91 haptoglobin-related protein Homo sapiens 95-98 19421858-2 2009 The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) inhibits prostate cancer development in vivo, and triggers reactive oxygen species (ROS)-dependent prostate cancer cell apoptosis in vitro. Fenretinide 23-52 haptoglobin-related protein Homo sapiens 55-58 19621427-3 2009 We present a novel case of a child who developed an LCH bone lesion while receiving a Phase I protocol therapy with oral fenretinide/Lym-X-Sorb (4-HPR/LXS) powder for neuroblastoma. Fenretinide 121-132 haptoglobin-related protein Homo sapiens 147-150 19482076-1 2009 N-(4-hydroxyphenyl) retinamide (4-HPR), as a synthetic retinoid, has been shown to inhibit carcinogenesis in a variety of cancers. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 34-37 19331667-2 2009 Patients are treated by maintenance CT. For some patients, an adjuvant retinoid therapy is proposed, such as the synthetic retinoid fenretinide (4-HPR), an apoptotic inducer. Fenretinide 132-143 haptoglobin-related protein Homo sapiens 147-150 19331667-6 2009 NB cell lines, i.e., IGR-N-91 and SH-EP, were treated with various doses of Fenretinide (4-HPR), then cytotoxicity was analyzed by MTS proliferation assay, apoptosis by the propidium staining method, gene or protein expressions by RT-PCR and immunoblotting and caspases activity by colorimetric protease assays. Fenretinide 76-87 haptoglobin-related protein Homo sapiens 91-94 19213559-4 2009 In this manuscript we use as an example the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR), a molecule with confirmed clinical applications in breast cancer adjuvant therapy to prevent cancer recurrence and under evaluation in neuroblastoma and glioblastoma treatment. Fenretinide 63-92 haptoglobin-related protein Homo sapiens 95-98 18066548-1 2008 PURPOSE: Pharmacokinetic data on fenretinide (4-HPR) are scant, thus limiting the rational use of the drug. Fenretinide 33-44 haptoglobin-related protein Homo sapiens 48-51 18515328-3 2008 Here, we show that the natural retinoid 9-cis retinoic acid (9cRA) and the synthetic retinoid fenretinide (4-HPR) specifically inhibit the functional up-regulation of CCR7 on maturing human DCs, without affecting early steps of DC maturation. Fenretinide 94-105 haptoglobin-related protein Homo sapiens 109-112 18164543-3 2008 N-(4-Hydroxyphenyl)retinamide (4-HPR) induced astrocytic differentiation and increased sensitivity to interferon-gamma (IFN-gamma) for apoptosis in human glioblastoma A172, LN18, and SNB19 cells. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 18425327-1 2008 The efficacy and mechanism of action of fenretinide (4-HPR), a vitamin A analogue, was investigated in a panel of six neuroblastoma cell lines and multicellular tumor spheroids. Fenretinide 40-51 haptoglobin-related protein Homo sapiens 55-58 18398104-3 2008 The synthetic cytotoxic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) is known to generate reactive oxygen species (ROS), and ROS have been shown to activate c-Jun kinase (JNK), which in turn phosphorylates and inhibits Mcl-1. Fenretinide 33-62 haptoglobin-related protein Homo sapiens 66-69 18602901-1 2008 N-(4-Hydroxyphenyl) retinamide (4-HPR) is a synthetic retinoid that has shown biological activity against several malignant tumors and minimal side effects in humans. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 34-37 18342855-1 2008 N-(4-hydroxyphenyl)retinamide (4HPR) is a synthetic retinoid that has been tested in clinical trials as a cancer chemopreventive drug. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 32-35 18174255-2 2008 Others and we have previously demonstrated apoptosis-inducing capacity of N-(4-hydroxyphenyl)retinamide (4-HPR) in malignant glioma cells. Fenretinide 74-103 haptoglobin-related protein Homo sapiens 107-110 17883277-1 2007 N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) has been shown to be active toward many tumors without appreciable side effects. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 46-49 18248980-0 2008 4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells. Fenretinide 0-25 haptoglobin-related protein Homo sapiens 28-31 18248980-1 2008 Recent studies exhibit that 4-hydroxyphenylretinamide (4HPR) decreases aromatase activity in breast and placental cells. Fenretinide 28-53 haptoglobin-related protein Homo sapiens 56-59 17955489-1 2008 Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR) is an aminophenol-containing synthetic retinoid derivative of all-trans-retinoic acid, which is a potent chemopreventive and antiproliferative agent against various cancers. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 46-49 17955489-1 2008 Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR) is an aminophenol-containing synthetic retinoid derivative of all-trans-retinoic acid, which is a potent chemopreventive and antiproliferative agent against various cancers. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 46-49 17883277-1 2007 N-(4-hydroxyphenyl)retinamide (fenretinide, 4-HPR) has been shown to be active toward many tumors without appreciable side effects. Fenretinide 31-42 haptoglobin-related protein Homo sapiens 46-49 17454142-1 2007 We have previously reported that, in leukemia cells, the cytotoxicity of the anticancer agent N-(4-hydroxyphenyl)retinamide (4-HPR) is mediated by mitochondria-derived reactive oxygen species (ROS) and cardiolipin peroxidation. Fenretinide 94-123 haptoglobin-related protein Homo sapiens 127-130 17213814-1 2007 Fenretinide (4-HPR) is a synthetic retinoid with antitumor activity, which induces apoptosis in cancer cell lines of different histotypes. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 16950796-5 2007 Among the synthetic agents, oltipraz and N-(4-hydroxyphenyl) retinamide (4-HPR) also increased MGMT expression, albeit to a lesser extent. Fenretinide 41-71 haptoglobin-related protein Homo sapiens 75-78 17112722-0 2007 Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs. Fenretinide 67-96 haptoglobin-related protein Homo sapiens 100-103 17112722-1 2007 Using solid phase-assisted synthesis and purification, a 49 member library of analogs of the mammary tumor chemopreventive retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been prepared. Fenretinide 132-161 haptoglobin-related protein Homo sapiens 165-168 17044020-1 2006 It has been demonstrated that the chemopreventive agent N-(4-hydroxyphenyl)retinamide (4-HPR) induces apoptotic cell death, but recent data has suggested that late stage/recurrent tumours lose their response to 4-HPR-induced cell death by mechanisms that are unknown. Fenretinide 56-85 haptoglobin-related protein Homo sapiens 89-92 17302189-8 2007 In one study, fenretinide (4-HPR) delayed development of ovarian cancer in women at increased risk of developing breast and ovarian cancer. Fenretinide 14-25 haptoglobin-related protein Homo sapiens 29-32 17044020-1 2006 It has been demonstrated that the chemopreventive agent N-(4-hydroxyphenyl)retinamide (4-HPR) induces apoptotic cell death, but recent data has suggested that late stage/recurrent tumours lose their response to 4-HPR-induced cell death by mechanisms that are unknown. Fenretinide 56-85 haptoglobin-related protein Homo sapiens 213-216 16520989-0 2006 Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells. Fenretinide 17-28 haptoglobin-related protein Homo sapiens 32-35 16675469-1 2006 N-(4-hydroxyphenyl)retinamide (4-HPR), a synthetic retinoid is under clinical evaluation as a therapeutic agent in a variety of cancers. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 16671099-1 2006 N-(4-Hydroxyphenyl)retinamide (4-HPR) is a nonclassical retinoid with cancer preventive effects in vivo and antiproliferative and apoptotic activities in vitro. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 16520989-1 2006 PURPOSES: N-(4-Hydroxyphenyl)-retinamide (4-HPR, Fenretinide) is a synthetic retinoid with cytotoxicity in acute lymphoblastic leukemia (ALL) cell lines. Fenretinide 10-40 haptoglobin-related protein Homo sapiens 44-47 16520989-1 2006 PURPOSES: N-(4-Hydroxyphenyl)-retinamide (4-HPR, Fenretinide) is a synthetic retinoid with cytotoxicity in acute lymphoblastic leukemia (ALL) cell lines. Fenretinide 49-60 haptoglobin-related protein Homo sapiens 44-47 16540676-1 2006 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a recently identified metabolite of fenretinide (4-HPR). Fenretinide 89-100 haptoglobin-related protein Homo sapiens 45-48 16540676-1 2006 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a recently identified metabolite of fenretinide (4-HPR). Fenretinide 89-100 haptoglobin-related protein Homo sapiens 104-107 16399227-1 2006 N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide) a synthetic retinoid is in clinical trials for the treatment of several malignancies. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 34-37 16302003-6 2006 Furthermore, we found that pharmacological intervention with low micromolar concentrations of N-(4-hydroxyphenyl)retinamide (4-HPR), which downmodulates cyclin D1, induced G1 arrest and apoptosis in rhabdoid cell lines. Fenretinide 94-123 haptoglobin-related protein Homo sapiens 127-130 16399227-1 2006 N-(4-hydroxyphenyl) retinamide (4-HPR, fenretinide) a synthetic retinoid is in clinical trials for the treatment of several malignancies. Fenretinide 39-50 haptoglobin-related protein Homo sapiens 34-37 17024972-0 2006 Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer. Fenretinide 46-75 haptoglobin-related protein Homo sapiens 79-82 17024972-6 2006 This study examines the effects of the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) in combination with cholecalciferol (vitamin D3) on growth, and on the expression of vimentin, matrix metalloproteinase-2 (MMP-2), and retinoid and vitamin D receptor expression, using the non-tumorigenic, human prostate epithelial cell line RWPE-1. Fenretinide 58-87 haptoglobin-related protein Homo sapiens 91-94 16091745-1 2005 Fenretinide (4-HPR) is a synthetic retinoid whose apoptosis-inducing effects have been demonstrated in many tumor types. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 16403262-1 2005 The retinoid N-4-hydroxyphenyl retinamide (4-HPR also known as fenretinide), a synthetic derivative of all trans retinoic acid (ATRA), has shown as an efficient chemopreventive, chemotherapeutic agent and a potent inducer of apoptosis in various cancer cell types in vitro, including leukemic cells. Fenretinide 13-41 haptoglobin-related protein Homo sapiens 45-48 16403262-1 2005 The retinoid N-4-hydroxyphenyl retinamide (4-HPR also known as fenretinide), a synthetic derivative of all trans retinoic acid (ATRA), has shown as an efficient chemopreventive, chemotherapeutic agent and a potent inducer of apoptosis in various cancer cell types in vitro, including leukemic cells. Fenretinide 63-74 haptoglobin-related protein Homo sapiens 45-48 15907982-2 2005 The synthetic retinoid, N-(4-hydroxyphenyl) retinamide (4-HPR), has been used in the chemoprevention of ovarian cancer. Fenretinide 24-54 haptoglobin-related protein Homo sapiens 58-61 16077929-1 2005 N-(4-hydroxyphenyl)retinamide (4HPR) is a synthetic retinoid that has shown efficacy in cancer chemoprevention and therapy possibly due to its ability to induce growth inhibition and apoptosis in cancer cells. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 32-35 16127422-6 2005 MCF-7/COX-2 cells were also resistant to the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) but not to its analog, all-trans retinoic acid. Fenretinide 54-83 haptoglobin-related protein Homo sapiens 87-90 16274795-1 2005 OBJECTIVE: To explore whether the mechanism of action of 4-hydroxyphenylretinamide (4-HPR, fenretidine), a synthetic retinoid, involves the functional activation of the nuclear hormone receptor class known as PPARs (peroxisome proliferator-activated receptors). Fenretinide 57-82 haptoglobin-related protein Homo sapiens 86-89 16230421-1 2005 N-(4-hydroxyphenyl) retinamide [4-HPR], a synthetic retinoid, has been shown to inhibit tumor cell growth, invasion, and metastasis by a mechanism that is not fully understood. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 34-37 16123139-5 2005 In this article, we investigated the ability of retinoids, such as 9-cis retinoic acid, all-trans retinoic acid, and N-4-hydroxyphenylretinamide (4-HPR), to sensitize the ductal epithelial cells of virgin mammary glands to DNA damage responses. Fenretinide 117-144 haptoglobin-related protein Homo sapiens 148-151 15917187-1 2005 All-trans-N-(4-hydroxyphenyl)retinamide (4HPR) is a synthetic retinoid that can induce apoptosis in many cancer cell lines. Fenretinide 0-39 haptoglobin-related protein Homo sapiens 42-45 15700313-0 2005 Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Fenretinide 20-31 haptoglobin-related protein Homo sapiens 35-38 16124896-1 2005 OBJECTIVE: To study the mechanism of the apoptosis induced by N-[4-hydroxyphenyl] retinamide (4-HPR) in bladder cancer cell line T24, and the involvement of DNA damage and repair. Fenretinide 62-92 haptoglobin-related protein Homo sapiens 96-99 15695235-2 2005 The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been shown to have a clinical chemopreventive activity in patients with premenopausal breast cancer. Fenretinide 23-52 haptoglobin-related protein Homo sapiens 56-59 16158929-1 2005 BACKGROUND: We have previously demonstrated that the synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) induces the overproduction of reactive oxygen species (ROS) in human leukemia cells, which in turn triggers the intrinsic (mitochondrial) apoptotic pathway. Fenretinide 72-102 haptoglobin-related protein Homo sapiens 106-109 15133197-1 2004 Retinoic acid and its amide derivative, N-(4-hydroxyphenyl)retinamide (4-HPR), have been proposed as chemopreventative and chemotherapeutic agents. Fenretinide 40-69 haptoglobin-related protein Homo sapiens 73-76 15862961-2 2005 Recent studies on aromatase inhibition by the synthetic retinoid 4HPR, also known as fenretinide, and the PPARgamma agonist 15-dPGJ(2) have implicated a direct receptor-independent, redox-sensitive mechanism of action. Fenretinide 85-96 haptoglobin-related protein Homo sapiens 66-69 15375546-7 2004 All-trans retinoic acid (atRA), 9-cis retinoic acid (9cRA), and 4-(hydroxyphenyl) retinamide (4-HPR) induced RARbeta2 protein expression exclusively in the benign MCF10A cells and the former two retinoids, mRNA expression in MCF10A and MCF10AT cells, but not in malignant, MCF10CA1a cells, suggesting that the loss of inducible RARbeta expression is associated with the progression and malignant transformation of MCF10A cells. Fenretinide 64-92 haptoglobin-related protein Homo sapiens 96-99 15448016-1 2004 PURPOSE: The synthetic retinoid fenretinide (4-HPR) exhibits preventive and therapeutic activity against ovarian tumors. Fenretinide 32-43 haptoglobin-related protein Homo sapiens 47-50 15289350-2 2004 We hypothesize that targeting minimal residual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decrease relapse. Fenretinide 83-113 haptoglobin-related protein Homo sapiens 117-120 15289350-2 2004 We hypothesize that targeting minimal residual disease with the cytotoxic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR; fenretinide) may decrease relapse. Fenretinide 122-133 haptoglobin-related protein Homo sapiens 117-120 15291358-1 2004 N-(4-hydroxyphenyl) retinamide (Fenretinide, 4-HPR) inhibits cell growth by inducing apoptosis in numerous tumor cell types including all-trans-retinoic acid (ATRA)-resistant tumor cells. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 47-50 15291358-1 2004 N-(4-hydroxyphenyl) retinamide (Fenretinide, 4-HPR) inhibits cell growth by inducing apoptosis in numerous tumor cell types including all-trans-retinoic acid (ATRA)-resistant tumor cells. Fenretinide 32-43 haptoglobin-related protein Homo sapiens 47-50 15756035-1 2005 PURPOSE: Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models. Fenretinide 9-20 haptoglobin-related protein Homo sapiens 24-27 15862961-0 2005 Aromatase inhibition by 15-deoxy-prostaglandin J(2) (15-dPGJ(2)) and N-(4-hydroxyphenyl)-retinamide (4HPR) is associated with enhanced ceramide production. Fenretinide 69-99 haptoglobin-related protein Homo sapiens 102-105 15816545-0 2005 Action of fenretinide (4-HPR) on ovarian cancer and endothelial cells. Fenretinide 10-21 haptoglobin-related protein Homo sapiens 25-28 15816545-1 2005 BACKGROUND: Fenretinide (4-HPR) is a synthetic retinoid that has been reported to inhibit the growth of cancer cell lines in vitro. Fenretinide 12-23 haptoglobin-related protein Homo sapiens 27-30 15297165-1 2004 OBJECTIVE: This trial examined the use of 4-hydroxyphenyl-retinamide (4-HPR), demonstrated to be a potent inhibitor of carcinogenesis in vitro and in animal models, in patients with cervical intraepithelial neoplasia (CIN) grades 2 to 3. Fenretinide 42-68 haptoglobin-related protein Homo sapiens 72-75 14765134-0 2004 N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Fenretinide 0-30 haptoglobin-related protein Homo sapiens 33-36 15013522-5 2004 Several anticancer agents, including the cytotoxic retinoid, fenretinide (4-HPR), have been shown to act, at least in part, by increasing tumor cell ceramide via de novo synthesis. Fenretinide 61-72 haptoglobin-related protein Homo sapiens 76-79 14519946-1 2003 4-(N-Hydroxyphenyl)retinamide (also known as 4-HPR or fenretinide), a synthetic amide of all-trans retinoic acid (RA), has been implicated as a promising anticancer agent associated with reducing the toxicity related to RA. Fenretinide 54-65 haptoglobin-related protein Homo sapiens 47-50 14592467-1 2003 The retinamide, N-(4-hydroxyphenyl)retinamide (4-HPR), has shown promising anti-tumor activity, but it is unclear whether this compound is hydrolyzed to all-trans retinoic acid (atRA) and if so, whether this plays any role in its chemotherapeutic activity. Fenretinide 16-45 haptoglobin-related protein Homo sapiens 49-52 14647238-1 2004 Fenretinide (HPR), a synthetic retinoid that exhibits lower toxicity than other retinoids, has shown preventive and therapeutic activity against ovarian tumors. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 13-16 14735468-1 2004 Fenretinide, 4-(N-hydroxyphenyl) retinamide (4-HPR), has demonstrated anticancer activity associated with a favorable toxicity profile and is now being investigated in several clinical trials. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 47-50 14767528-4 2004 Like RA, 4-hydroxyphenyl retinamide (4-HPR) and 4-APRE, 4-BPRE was an active ligand for all three subtypes of RAR, but not for RXR, as determined by transcription assays in COS-1 cells. Fenretinide 9-35 haptoglobin-related protein Homo sapiens 39-42 14555987-0 2003 HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. Fenretinide 42-71 haptoglobin-related protein Homo sapiens 75-78 14555987-1 2003 The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR also known as fenretinide) is a potent inducer of apoptosis in breast cancer cells. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 46-49 14555987-1 2003 The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR also known as fenretinide) is a potent inducer of apoptosis in breast cancer cells. Fenretinide 64-75 haptoglobin-related protein Homo sapiens 46-49 14604280-0 2003 N-(4-Hydroxyphenyl)retinamide (4-HPR) induces leukemia cell death via generation of reactive oxygen species. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 14604280-1 2003 The role of reactive oxygen species (ROS) in the cytotoxicity of N-(4-hydroxyphenyl)retinamide (4-HPR) was studied with use of the B-precursor lymphoblastic leukemia cell line YCUB-2. Fenretinide 65-94 haptoglobin-related protein Homo sapiens 98-101 13679861-1 2003 N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a potent chemopreventive agent whose effect has been suggested to involve apoptosis induction. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 13679861-1 2003 N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) is a potent chemopreventive agent whose effect has been suggested to involve apoptosis induction. Fenretinide 38-49 haptoglobin-related protein Homo sapiens 33-36 12537979-0 2003 N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Fenretinide 32-43 haptoglobin-related protein Homo sapiens 47-50 12880980-1 2003 Retinoids are derivatives of vitamin A that include all trans-retinoic acid (ATRA), 13-cis-retinoic acid, (13-cis-RA), and fenretinide (4-HPR). Fenretinide 123-134 haptoglobin-related protein Homo sapiens 138-141 12843642-1 2003 Retinoic acid (RA), a potent inducer of cell differentiation, and N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), a potent inducer of apoptosis, are well known as anticancer agents that are administered orally to patients for leukemia, breast and prostate cancer, respectively. Fenretinide 66-95 haptoglobin-related protein Homo sapiens 99-102 12843642-1 2003 Retinoic acid (RA), a potent inducer of cell differentiation, and N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide), a potent inducer of apoptosis, are well known as anticancer agents that are administered orally to patients for leukemia, breast and prostate cancer, respectively. Fenretinide 104-115 haptoglobin-related protein Homo sapiens 99-102 12855611-1 2003 PURPOSE: The synthetic retinoid N-(4-hydroxyphenyl)retinamide [4-HPR (or fenretinide)] has preclinical and clinical preventive activity in breast carcinogenesis. Fenretinide 32-61 haptoglobin-related protein Homo sapiens 65-68 12855611-1 2003 PURPOSE: The synthetic retinoid N-(4-hydroxyphenyl)retinamide [4-HPR (or fenretinide)] has preclinical and clinical preventive activity in breast carcinogenesis. Fenretinide 73-84 haptoglobin-related protein Homo sapiens 65-68 12619033-2 2003 We investigated the influence of androgen stimulation with testosterone on N-(4-hydroxyphenyl)retinamide (4-HPR)-induced apoptosis in the androgen-sensitive prostate cancer cell line LNCaP. Fenretinide 75-104 haptoglobin-related protein Homo sapiens 108-111 12796365-1 2003 PURPOSE: Fenretinide (4HPR), a synthetic retinoid, induces apoptosis in neuroblastoma cells. Fenretinide 9-20 haptoglobin-related protein Homo sapiens 23-26 12736045-6 2003 RESULTS: LNCaP cells were five times more sensitive to N-(4-hydroxyphenyl)retinamide (4-HPR), a synthetic retinoid, compared with PC-3 cells. Fenretinide 55-84 haptoglobin-related protein Homo sapiens 88-91 12537979-2 2003 N-(4-Hydroxyphenyl)-all-trans-retinamide (fenretinide, 4-HPR) is a synthetic ATRA derivative with chemopreventive and cytotoxic activity against various cancer cell lines including myeloid leukemia. Fenretinide 0-40 haptoglobin-related protein Homo sapiens 57-60 12537979-2 2003 N-(4-Hydroxyphenyl)-all-trans-retinamide (fenretinide, 4-HPR) is a synthetic ATRA derivative with chemopreventive and cytotoxic activity against various cancer cell lines including myeloid leukemia. Fenretinide 42-53 haptoglobin-related protein Homo sapiens 57-60 12353227-0 2002 Upregulation of GADD153 expression in the apoptotic signaling of N-(4-hydroxyphenyl)retinamide (4HPR). Fenretinide 65-94 haptoglobin-related protein Homo sapiens 97-100 12540501-1 2003 OBJECTIVES: To assess, in women participating in a breast cancer prevention trialon fenretinide (4-HPR), the relationship of drug and retinol levels with the risk of second breast malignancy, taking into account age and menopausal status. Fenretinide 84-95 haptoglobin-related protein Homo sapiens 99-102 12517593-2 2003 A promising oral retinoid, 4-hydroxyphenylretinamide (4-HPR) induced apoptosis through non-retinoic acid-mediated pathways and is being studied in National Cancer Institute phase II trials in several organ sites. Fenretinide 27-52 haptoglobin-related protein Homo sapiens 56-59 12388538-2 2002 Herein we investigate the molecular mechanism of ceramide signaling in endothelial apoptosis induced by fenretinide (N-(4-hydroxyphenyl)retinamide (4-HPR)). Fenretinide 104-115 haptoglobin-related protein Homo sapiens 150-153 12388538-2 2002 Herein we investigate the molecular mechanism of ceramide signaling in endothelial apoptosis induced by fenretinide (N-(4-hydroxyphenyl)retinamide (4-HPR)). Fenretinide 117-146 haptoglobin-related protein Homo sapiens 150-153 12417027-1 2002 Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR), is a synthetic amide of all-trans-retinoic acid (RA), which inhibits cell growth, induces apoptosis, and is an antioxidant, and cancer chemopreventive and antiproliferative agent. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 46-49 12417027-1 2002 Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR), is a synthetic amide of all-trans-retinoic acid (RA), which inhibits cell growth, induces apoptosis, and is an antioxidant, and cancer chemopreventive and antiproliferative agent. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 46-49 11807954-1 2002 To explore the mechanisms underlying the pro-apoptotic effects of the synthetic retinoid N-4-(hydroxyphenyl)retinamide (4-HPR) on LNCaP human prostate cancer cells, we used the differential display-polymerase chain reaction (DD-PCR) technique to identify 4-HPR-responsive genes. Fenretinide 89-118 haptoglobin-related protein Homo sapiens 122-125 12124800-1 2002 The synthetic retinoid fenretinide [N-(4-hydroxyphenyl)retinamide, 4-HPR] has demonstrated growth inhibition and induction of apoptosis of various malignant cells, including lung cancer cell lines. Fenretinide 23-34 haptoglobin-related protein Homo sapiens 69-72 12124800-1 2002 The synthetic retinoid fenretinide [N-(4-hydroxyphenyl)retinamide, 4-HPR] has demonstrated growth inhibition and induction of apoptosis of various malignant cells, including lung cancer cell lines. Fenretinide 36-65 haptoglobin-related protein Homo sapiens 69-72 12481423-1 2002 N-(4-Hydroxyphenyl)retinamide (4-HPR) induces apoptosis in breast cancer cells; however, the molecular basis by which 4-HPR induces apoptosis is not well understood. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 12481423-1 2002 N-(4-Hydroxyphenyl)retinamide (4-HPR) induces apoptosis in breast cancer cells; however, the molecular basis by which 4-HPR induces apoptosis is not well understood. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 120-123 12161154-1 2002 Retinoic acid analogues such as N-(4-hydroxyphenyl)retinamide (4-HPR) are effective chemopreventatives and chemotherapeutics for numerous types of cancer. Fenretinide 32-61 haptoglobin-related protein Homo sapiens 65-68 12175543-0 2002 N-(4-hydroxyphenyl)retinamide (4-HPR) modulates GADD45 expression in radiosensitive bladder cancer cell lines. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 12175543-1 2002 We previously demonstrated that N-(4-hydroxyphenyl)retinamide (4-HPR) and gamma-irradiation, when used in combination, had a synergistic effect in inducing apoptosis in bladder cancer cells, suggesting that 4-HPR may increase radiosensitivity in bladder cancer cells. Fenretinide 32-61 haptoglobin-related protein Homo sapiens 65-68 12175543-1 2002 We previously demonstrated that N-(4-hydroxyphenyl)retinamide (4-HPR) and gamma-irradiation, when used in combination, had a synergistic effect in inducing apoptosis in bladder cancer cells, suggesting that 4-HPR may increase radiosensitivity in bladder cancer cells. Fenretinide 32-61 haptoglobin-related protein Homo sapiens 209-212 11986953-1 2002 The retinoid, N-(4-hydroxyphenyl)retinamide (4-HPR), mediates p53-independent cytotoxicity and can increase reactive oxygen species and ceramide in solid tumor cell lines. Fenretinide 14-43 haptoglobin-related protein Homo sapiens 47-50 11921197-6 2002 The Italian trial of fenretinide (4-HPR) in women with stage I breast cancer randomized women to fenretinide or no intervention. Fenretinide 21-32 haptoglobin-related protein Homo sapiens 36-39 11807954-1 2002 To explore the mechanisms underlying the pro-apoptotic effects of the synthetic retinoid N-4-(hydroxyphenyl)retinamide (4-HPR) on LNCaP human prostate cancer cells, we used the differential display-polymerase chain reaction (DD-PCR) technique to identify 4-HPR-responsive genes. Fenretinide 89-118 haptoglobin-related protein Homo sapiens 257-260 11705848-2 2001 We tested N-(4-hydroxyphenyl)retinamide (4-HPR), a promising oral retinoid that has been shown to induce apoptosis through nonretinoic receptor acid-mediated pathways, for its toxicity and efficacy against CIN 2/3. Fenretinide 10-39 haptoglobin-related protein Homo sapiens 43-46 11745408-2 2001 The synthetic retinoid fenretinide (HPR) inhibits carcinogenesis in various animal models. Fenretinide 23-34 haptoglobin-related protein Homo sapiens 36-39 11551492-0 2001 N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 11483862-0 2001 Mechanism of fenretinide (4-HPR)-induced cell death. Fenretinide 13-24 haptoglobin-related protein Homo sapiens 28-31 11483862-1 2001 4-HPR (fenretinide) is a synthetic analog of retinoic acid (RA) whose potential as a chemopreventative agent has gained support from in vitro and animal experiments and in limited clinical trials. Fenretinide 7-18 haptoglobin-related protein Homo sapiens 2-5 11551492-3 2001 This study focuses on the ability of the synthetic retinoid, N-(4-hydroxyphenyl)-retinamide (4-HPR), to reverse changes associated with malignant transformation and tumor progression, towards a normal phenotype. Fenretinide 61-91 haptoglobin-related protein Homo sapiens 95-98 11287445-3 2001 Some novel retinoids, such as fenretinide, i.e., N-(4-hydroxyphenyl)retinamide (4-HPR), induce apoptosis through retinoic acid receptor-independent mechanisms; however, they appear to do so only at concentrations above those achieved in clinical chemoprevention trials. Fenretinide 30-41 haptoglobin-related protein Homo sapiens 82-85 11489831-0 2001 Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. Fenretinide 27-38 haptoglobin-related protein Homo sapiens 42-45 11489831-4 2001 In this report, we evaluate the in vitro effects of N-(4-hydroxyphenyl) retinamide (4-HPR) with and without anti-CD20 antibodies in B-cell lymphoma lines. Fenretinide 52-82 haptoglobin-related protein Homo sapiens 86-89 11431347-1 2001 The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 46-49 11431347-1 2001 The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 186-189 11431347-1 2001 The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl. Fenretinide 51-62 haptoglobin-related protein Homo sapiens 46-49 11431347-1 2001 The retinoid N-(4-hydroxyphenyl)retinamide (4-HPR; fenretinide) is cytotoxic to a variety of cancer cell lines, and we previously showed an association between ceramide generation and 4-HPR cytotoxicity for neuroblastoma cell lines (B. J. Maurer et al., J. Natl. Fenretinide 51-62 haptoglobin-related protein Homo sapiens 186-189 11412986-2 2001 The synthesis of a nonhydrolyzable, carbon-linked analogue (4-HBR) of the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) using Umpolung methods is described. Fenretinide 83-112 haptoglobin-related protein Homo sapiens 116-119 11384104-1 2001 We investigated whether the efficacy of fenretinide (HPR) against ovarian tumours may be limited by induction of resistance. Fenretinide 40-51 haptoglobin-related protein Homo sapiens 53-56 11287445-3 2001 Some novel retinoids, such as fenretinide, i.e., N-(4-hydroxyphenyl)retinamide (4-HPR), induce apoptosis through retinoic acid receptor-independent mechanisms; however, they appear to do so only at concentrations above those achieved in clinical chemoprevention trials. Fenretinide 49-78 haptoglobin-related protein Homo sapiens 82-85 11166911-1 2001 Fenretinide [N-(4-Hydroxyphenyl)retinamide, 4-HPR] (10(-10)-10(-6) M) treatment of HT-29 human colon cancer cells for 24-72 h significantly inhibited their growth. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 46-49 11295632-2 2001 A phase 2 chemoprevention trial of 4-hydroxyphenyl retinamide (4-HPR) versus placebo was conducted in men with a histologic diagnosis of early prostate cancer and scheduled to have radical prostatectomy. Fenretinide 35-61 haptoglobin-related protein Homo sapiens 65-68 11107126-7 2000 Both parental and RA-resistant lines showed 2-4 logs of cell kill in response to N-(4-hydroxyphenyl)retinamide (4- HPR, fenretinide). Fenretinide 81-110 haptoglobin-related protein Homo sapiens 115-118 11106681-1 2000 BACKGROUND: We previously reported that N-(4-hydroxyphenyl)retinamide (4-HPR, fenretinide) treatment caused large increases of ceramide levels in neuroblastoma cell lines and induced cell death by a combination of apoptosis and necrosis through p53 (also known as TP53)-independent and caspase-independent pathways. Fenretinide 40-69 haptoglobin-related protein Homo sapiens 73-76 11078493-1 2000 PURPOSE: To examine the feasibility of using fenretinide (4-HPR) for the prevention and treatment of prostate cancer. Fenretinide 45-56 haptoglobin-related protein Homo sapiens 60-63 10918204-4 2000 We have previously shown that the synthetic retinoid fenretinide (4-HPR) lowers plasma IGF-I in pre-menopausal breast cancer patients. Fenretinide 53-64 haptoglobin-related protein Homo sapiens 68-71 11122886-1 2000 Retinoids are derivatives of vitamin A that include all- trans-retinoic acid (ATRA), 13-cis-retinoic acid, (13-cis-RA), and fenretinide (4-HPR). Fenretinide 124-135 haptoglobin-related protein Homo sapiens 139-142 11027625-1 2000 Fenretinide (4-HPR) is a synthetic retinoid with cancer chemopreventative potential and clinically manageable side effects, compared to the prototype retinoid, all-trans retinoic acid (RA). Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 10969771-1 2000 Fenretinide (4-HPR) is a synthetic retinoid that displays a broad range of biological effects and has also demonstrated clinical efficacy as a chemopreventative agent. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 15-18 10917548-1 2000 The effect of the chemopreventive synthetic retinoid N-(4-hydroxyphenyl)-retinamide (4-HPR) on aromatase activity and expression was examined. Fenretinide 53-83 haptoglobin-related protein Homo sapiens 87-90 10955773-3 2000 One such strategy is to use retinoids like N-(4-hydroxyphenyl)retinamide (4-HPR), which has been found to possess chemopreventive activities in preclinical studies. Fenretinide 43-72 haptoglobin-related protein Homo sapiens 76-79 10772821-1 2000 N-(4-hydroxyphenyl)retinamide (4-HPR) is a synthetic apoptosis-inducing retinoid with cancer chemopreventive properties and lower toxicity than all-trans retinoic acid. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 10824459-1 2000 Previous investigations have demonstrated that a synthetic retinoid, N-(4-hydroxyphenyl) retinamide (4-HPR), inhibits the invasion of prostate adenocarcinoma in vitro. Fenretinide 69-99 haptoglobin-related protein Homo sapiens 103-106 10762020-5 2000 Both tamoxifen and the synthetic retinoid fenretinide (4-HPR) have been shown to decrease plasma IGF-I levels. Fenretinide 42-53 haptoglobin-related protein Homo sapiens 57-60 10570055-1 1999 N-(4-Hydroxyphenyl)retinamide (4-HPR), a retinoic acid analog, induces apoptosis in several cell types. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 10572559-17 1999 Based on experimental studies, the vitamin A analogue 4-hydroxyphenyl retinamide (4-HPR) was shown to delay and reduce carcinogen-induced breast cancer. Fenretinide 54-80 haptoglobin-related protein Homo sapiens 84-87 10448131-3 1999 All-trans-N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) is a synthetic retinoid that is reported to have fewer side-effects compared to naturally occurring retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid. Fenretinide 0-39 haptoglobin-related protein Homo sapiens 42-45 10448131-3 1999 All-trans-N-(4-hydroxyphenyl)retinamide (4HPR or fenretinide) is a synthetic retinoid that is reported to have fewer side-effects compared to naturally occurring retinoids such as all-trans retinoic acid (ATRA) and 9-cis retinoic acid. Fenretinide 49-60 haptoglobin-related protein Homo sapiens 42-45 10357800-1 1999 4-Hydroxyphenylretinamide (4-HPR) is a synthetic retinoid with minimal toxicity and favorable pharmacokinetics during long-term administration to patients in clinical trials. Fenretinide 0-25 haptoglobin-related protein Homo sapiens 29-32 10706389-1 2000 Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown. Fenretinide 0-11 haptoglobin-related protein Homo sapiens 46-49 10706389-1 2000 Fenretinide, N-(4-hydroxyphenyl)retinamide (4-HPR), is a cancer chemopreventive and antiproliferative agent whose mechanism of action is unknown. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 46-49 10637240-1 2000 PURPOSE: N-(4-hydroxyphenyl) retinamide (?4-HPR, Fenretinide; R.W. Fenretinide 9-39 haptoglobin-related protein Homo sapiens 44-47 10523855-8 1999 In contrast, N-(4-hydroxyphenyl)retinamide (4HPR), a reported transcriptional activator of RARgamma was shown to potently induce growth inhibition and apoptosis in both NT2/D1 and NT2/D1-R1 cells. Fenretinide 13-42 haptoglobin-related protein Homo sapiens 45-48 10393722-1 1999 BACKGROUND: The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide) is toxic to myeloid leukemia and cervical carcinoma cell lines, probably in part due to its ability to increase levels of reactive oxygen species (ROS). Fenretinide 35-64 haptoglobin-related protein Homo sapiens 68-71 10393722-1 1999 BACKGROUND: The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR or fenretinide) is toxic to myeloid leukemia and cervical carcinoma cell lines, probably in part due to its ability to increase levels of reactive oxygen species (ROS). Fenretinide 75-86 haptoglobin-related protein Homo sapiens 68-71 10334206-2 1999 In this study, we used cell proliferation and telomerase in MNU (N-methyl-N-nitrosourea)-induced mammary carcinomas as targets for assessing the response of tumor cells to 4-(hydroxyphenyl)retinamide (4-HPR), a known inhibitor of mammary carcinogenesis in animal models and premenopausal women. Fenretinide 172-199 haptoglobin-related protein Homo sapiens 203-206 10432011-0 1999 Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Fenretinide 72-101 haptoglobin-related protein Homo sapiens 105-108 10432011-4 1999 This study focuses on the ability of N-(4-hydroxyphenyl)-retinamide (4-HPR), a synthetic retinoid, to reverse malignant characteristics towards a normal phenotype, using the human prostate carcinoma cell line DU-145. Fenretinide 37-67 haptoglobin-related protein Homo sapiens 71-74 10188730-4 1999 Previously, we reported that the synthetic retinoid fenretinide (HPR) is an inducer of apoptosis in neuroblastoma (NB) cells, sharing the neuroectodermal origin with melanoma cells. Fenretinide 52-63 haptoglobin-related protein Homo sapiens 65-68 9639444-0 1998 Effects of fenretinide (4-HPR) on dark adaptation. Fenretinide 11-22 haptoglobin-related protein Homo sapiens 26-29 9923820-1 1999 PURPOSE: Fenretinide [N-(4-hydroxyphenyl)retinamide, 4HPR], a synthetic retinoid, is a potent inducer of apoptosis in small-cell lung cancer (SCLC) cell lines that may act through the generation of reactive oxygen species, suggesting that it may enhance the activity of other cytotoxic agents. Fenretinide 9-20 haptoglobin-related protein Homo sapiens 54-57 9923820-1 1999 PURPOSE: Fenretinide [N-(4-hydroxyphenyl)retinamide, 4HPR], a synthetic retinoid, is a potent inducer of apoptosis in small-cell lung cancer (SCLC) cell lines that may act through the generation of reactive oxygen species, suggesting that it may enhance the activity of other cytotoxic agents. Fenretinide 22-51 haptoglobin-related protein Homo sapiens 54-57 10325501-1 1999 An NCI-sponsored, phase II trial of N-(4-hydroxyphenyl)- retinamide (4-HPR) in patients with organ-confined prostate cancer in the period prior to radical prostatectomy was carried out. Fenretinide 36-67 haptoglobin-related protein Homo sapiens 71-74 10578478-1 1999 N-(4 hydroxyphenyl)retinamide (4-HPR), a synthetic derivative of all-trans-retinoic acid, induces DNA synthesis arrest and apoptosis in human breast cancer cells in a dose- and time-dependent manner. Fenretinide 0-29 haptoglobin-related protein Homo sapiens 33-36 9639444-1 1998 OBJECTIVES: To assess the alterations in dark adaptation induced by low (200 mg/d) doses of fenretinide (4-HPR), to assess whether these effects were cumulative and whether they were reversible, and to attempt to elucidate the mechanism underlying the changes in night vision. Fenretinide 92-103 haptoglobin-related protein Homo sapiens 107-110 9797705-0 1998 Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. Fenretinide 14-43 haptoglobin-related protein Homo sapiens 47-50 9797705-1 1998 A clinical trial of N-[4-hydroxyphenyl]retinamide (4-HPR) has been in progress for the past 4 years to evaluate its role in chemoprevention of breast cancer. Fenretinide 20-49 haptoglobin-related protein Homo sapiens 53-56 9554442-1 1998 BACKGROUND: The synthetic retinoid N-(4-hydroxyphenyl) retinamide (4HPR) can inhibit the growth of tumor cells. Fenretinide 35-65 haptoglobin-related protein Homo sapiens 68-71 9560096-3 1998 The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide) (HPR) has significant antiproliferative activity against a number of animal and human malignancies and has been used in clinical trials as a chemopreventive agent in patients with breast and prostate cancer and oral leukoplakia. Fenretinide 23-34 haptoglobin-related protein Homo sapiens 68-71 9560096-3 1998 The synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide) (HPR) has significant antiproliferative activity against a number of animal and human malignancies and has been used in clinical trials as a chemopreventive agent in patients with breast and prostate cancer and oral leukoplakia. Fenretinide 36-65 haptoglobin-related protein Homo sapiens 68-71 9316650-1 1997 BACKGROUND: Although fenretinide (4-HPR) is currently being evaluated in a phase II clinical study for the chemoprevention of prostate cancer [Greenwald et al. Fenretinide 21-32 haptoglobin-related protein Homo sapiens 36-39 9526578-2 1997 The Fenretinide (4-HPR) Breast Cancer Study is a randomized multicenter clinical trial originally designed and conducted by the investigators of the Istituto Nazionale Tumori of Milan. Fenretinide 4-15 haptoglobin-related protein Homo sapiens 19-22